Zakiyatul Faizah and Bella Amanda and Faisal Yusuf Ashari and Efta Triastuti and Rebecca Oxtoby and Anny Setijo Rahaju and M Aminudin Aziz and Maria Inge Lusida and Delvac Oceandy (2020) Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice. Molecules Journal, 25 (19). pp. 1420-3049. ISSN 1420-3049

	Text (Artikel) 3 ARTIKEL.pdf Download (1MB)
	Text (Laik Etik) 3 etik.pdf Download (217kB)
	Text (Turnitin) 3 turnitin.pdf Download (4MB)
	Text (Kualitas Karil & Kesesuaian Bidang Ilmu) Karil (1)-3.pdf Download (240kB)

Abstract

Abstract Diabetes mellitus (DM) is one of the major causes of death in the world. There are two types of DM-type 1 DM and type 2 DM. Type 1 DM can only be treated by insulin injection whereas type 2 DM is commonly treated using anti-hyperglycemic agents. Despite its effectiveness in controlling blood glucose level, this therapeutic approach is not able to reduce the decline in the number of functional pancreatic β cells. MST1 is a strong pro-apoptotic kinase that is expressed in pancreatic β cells. It induces β cell death and impairs insulin secretion. Recently, a potent and specific inhibitor for MST1, called XMU-MP-1, was identified and characterized. We hypothesized that treatment with XMU-MP-1 would produce beneficial effects by improving the survival and function of the pancreatic β cells. We used INS-1 cells and STZ-induced diabetic mice as in vitro and in vivo models to test the effect of XMU-MP-1 treatment. We found that XMU-MP-1 inhibited MST1/2 activity in INS-1 cells. Moreover, treatment with XMU-MP-1 produced a beneficial effect in improving glucose tolerance in the STZ-induced diabetic mouse model. Histological analysis indicated that XMU-MP-1 increased the number of pancreatic β cells and enhanced Langerhans islet area in the severe diabetic mice. Overall, this study showed that MST1 could become a promising therapeutic target for diabetes mellitus.

Actions (login required)

View Item